Every year, lung cancer professionals from across the globe gather to connect and learn at the World Conference for Lung Cancer (WCLC). Members of the GO2 team just returned from WCLC 2023 hosted in Singapore, where they presented GO2’s [...]
Ask the Experts: "I have small cell lung cancer and my doctor mentioned the option of having prophylactic cranial irradiation (PCI) to help prevent the cancer from spreading to my brain. I know some people decide to have PCI [...]
Question: My tumor’s original biopsy showed that I had non-small cell lung cancer with an EGFR biomarker. Recently, the cancer started progressing and my most recent biopsy shows that I have transformed small cell lung cancer. What does this [...]
Authors: Renee Botello, MSc., Treatment and Trials Navigator; Andrew Ciupek, PhD, Associate Director, Clinical Research; Chief Scientific Officer Jennifer C. King, PhD; Shanada Monestime, PharmD, BCOP, Director, Community Engaged Research Every person’s cancer is different, which is why we [...]
Authors: Andrew Ciupek, PhD, Associate Director, Clinical Research; Jennifer C. King, PhD, Chief Scientific Officer; Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program Doctors and scientists from around the world who are passionate about lung cancer convened last month [...]
Small cell lung cancer (SCLC) can be a highly aggressive form of lung cancer and can be difficult to treat. It is the rarest of the major lung cancer types and represents just 15% of all diagnoses. Unfortunately, few [...]
Author: Jennifer C. King, PhD, Chief Scientific Officer People diagnosed with small cell lung cancer (SCLC) have historically had limited treatment options—but researchers are working to change that. At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, [...]
GO2 for Lung Cancer team pictured: Joelle Fathi, DNP, RN, ARNP, FAAN; Daniel Saez, MSc; Jennifer C. King, PhD By Jennifer C. King, PhD, Chief Scientific Officer and Daniel Saez, MSc, Manager, LungMATCH Navigation Program The [...]
Author: Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program, GO2 for Lung Cancer People with lung cancer receiving treatment may encounter acquired drug resistance—a reduction in treatment effectiveness over time. Tagrisso (osimertinib) is currently a frontline treatment for people [...]
Authors: Amy Kampschroeder MA, OTR/L, CHES, Manager, Patient Outreach and Special Initiatives and Daniel A. Saez, MSc, Manager, LungMATCH Navigation Program In 2021, one of GO2 for Lung Cancer’s priorities continued to be bringing lung cancer education and empowerment to patients to help [...]